UBS AG Form 424B8 December 17, 2018

The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement, the Prospectus Supplement, the accompanying Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Securities in any state where the offer or sale is not permitted.

Subject to Completion

Dated November 12, 2018 PRELIMINARY TERMS SUPPLEMENT Filed Pursuant to Rule 424(b)(8) Registration Statement No. 333-225551 **Preliminary Terms Supplement**

UBS AG Trigger Phoenix Autocallable Optimization Securities

UBS AG \$ Securities Linked to the shares of iShares® MSCI Brazil ETF due on or about November 17, 2020

Final Terms

Issuer UBS AG, London Branch

Principal \$10.00 per security. The Securities are offered at a minimum investment of 100 Securities at \$10.00 per

Amount Security (representing a \$1,000 investment) and integral multiples of \$10.00 in excess thereof.

Term Approximately 24 months, unless called earlier.

Underlying

The shares of iShares® MSCI Brazil ETF Asset

Coupon

Contingent If the closing price of the underlying asset is equal to or greater than the coupon barrier on any observation date, UBS will pay you the contingent coupon applicable to such observation date.

> If the closing price of the underlying asset is less than the coupon barrier on any observation date, the contingent coupon applicable to such observation date will not be payable and UBS will not make any payment to you on the relevant coupon payment date.

The contingent coupon will be a fixed amount based upon equal quarterly installments at the per annum contingent coupon rate. Contingent coupons are not guaranteed and UBS will not pay you the contingent coupon for any observation date on which the closing price of the underlying asset is less than the coupon barrier. The table below sets forth each observation date and a hypothetical contingent coupon for the Securities. The table below assumes a contingent coupon rate of 6.82% per annum. The actual contingent coupon rate will be set at the time the trade is placed on the trade date. Amounts in the table below may have been rounded for ease of analysis.

Observation Date* Contingent Coupon (per security)

12-Feb-2019 \$0.1705 13-May-2019 \$0.1705 12-Aug-2019 \$0.1705

12-Nov-2019	\$0.1705
12-Feb-2020	\$0.1705
12-May-2020	\$0.1705
12-Aug-2020	\$0.1705
12-Nov-2020	\$0.1705

* Observation dates are subject to the market disruption event provisions set forth in the accompanying product supplement.

Contingent Coupon Rate 6.82% to 7.76% per annum (or approximately 1.705% to 1.940% per outstanding quarter). The actual

contingent coupon rate will be set at the time the trade is placed on the trade date.

The Securities will be called automatically if the closing price of the underlying asset on any observation date is equal to or greater than the initial price. If the Securities are called on any

Automatic Call observation date, UBS will pay you on the corresponding coupon payment date a cash payment per

Feature

Security equal to your principal amount plus the contingent coupon otherwise due on such date pursuant to the contingent coupon feature. No further amounts will be owed to you under the

Securities.

Payment at Maturity (per Security) If the Securities are not called and the final price is equal to or greater than the trigger price and coupon barrier, UBS will pay you a cash payment per Security on the maturity date equal to your

principal plus the contingent coupon otherwise due on the maturity date.

If the Securities are not called and the final price is less than the trigger price, UBS will pay you a cash payment on the maturity date of significantly less than the principal amount, if anything, resulting in a loss of principal that is proportionate to the decline of the underlying asset, for an amount equal to \$10

+ (\$10 x underlying return).

Underlying

Final Price - Initial Price

Return

Initial Price

On any trading day, the last reported sale price (or, in the case of NASDAQ, the official closing price)

Closing Price

of the underlying asset during the principal trading session on the principal national securities

exchange on which it is listed for trading, as determined by the calculation agent.

(Cover Continued on Next Page)

1

(Cover Continued from Prior Page)

The closing price of the underlying asset on the trade date, as determined by the calculation agent

Initial Price and as may be adjusted in the case of certain corporate events, as described in the accompanying

product supplement.

Trigger Both 60.00% of the initial price of the underlying asset, as determined by the calculation agent

Price/Coupon and as may be adjusted in the case of certain corporate events, as described in the accompanying

Barrier product supplement.

The closing price of the underlying asset on the final valuation date, as determined by the

Final Price calculation agent and subject to adjustments in the case of certain corporate events, as described

in the accompanying product supplement.

Trade Date November 12, 2018 Settlement Date November 14, 2018

Final Valuation November 12, 2020. The final valuation date may be subject to postponement in the event of a

Date market disruption event, as described in the accompanying product supplement.

Maturity Date

November 17, 2020. The maturity date may be subject to postponement in the event of a market

disruption event, as described in the accompanying product supplement.

Coupon Payment Three business days following each observation date, except the coupon payment date for the

Dates final valuation date will be the maturity date.

CUSIP [n]
ISIN [n]
Valoren [n]

The estimated initial value based on an issuance size of approximately \$100,000 of the Securities as of the trade date is expected to be between 93.71% and 96.21% of the issue price to the public for Securities linked to the underlying asset. The range of the estimated initial value of the Securities was determined on the date of this preliminary terms supplement by reference to UBS' internal pricing models, inclusive of the internal funding rate. For more information about secondary market offers and the estimated initial value of the Securities, see "Key Risks - Fair value considerations" and "Key Risks - Limited or no secondary market and secondary market price considerations" in this preliminary terms supplement.

Notice to investors: the Securities are significantly riskier than conventional debt instruments. The issuer is not necessarily obligated to repay the full principal amount of the Securities at maturity, and the Securities may have the same downside market risk as the underlying asset. This market risk is in addition to the credit risk inherent in purchasing a debt obligation of UBS. You should not purchase the Securities if you do not understand or are not comfortable with the significant risks involved in investing in the Securities.

You should carefully consider the risks described under "Key Risks" in this preliminary terms supplement, under "Key Risks" beginning on page 3 of the prospectus supplement and under "Risk Factors" beginning on page PS-9 of the accompanying product supplement before purchasing any Securities. Events relating to any of those risks, or other risks and uncertainties, could adversely affect the market value of, and the return on, your Securities. You may lose a significant portion or all of your initial investment in the Securities. The Securities will not be listed or displayed on any securities exchange or any electronic communications network.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these Securities or passed upon the adequacy or accuracy of this preliminary terms supplement, the previously delivered prospectus supplement, the accompanying product supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

The Securities are not bank deposits and are not insured by the Federal Deposit Insurance Corporation or any other governmental agency.

See "Additional Information about UBS and the Securities" in this preliminary terms supplement. The Securities we are offering will have the terms set forth in the Prospectus Supplement dated November 1, 2018 relating to the Securities, the accompanying product supplement, the accompanying prospectus and this preliminary terms supplement.

Offering of Securities